lipid-nanoparticles

Documents about lipid-nanoparticles

• Next-generation vaccine adjuvants: Integrating nanotechnology, systems immunology, and computational approaches for precision vaccinology#642691Europe PMC
• Nose-to-Brain Delivery of mRNA-Loaded Lipid Nanoparticles Bypasses the Blood–Brain Barrier for Effective Brain Disease Therapy#202131Figshare
• Raw data of Multiepitope mRNA vaccine against Fasciola hepatica confers T-cell-mediated protection in mice [Dataset]#339934Gestión del Repositorio Documental de la Universidad de Salamanca
• Targeted delivery of mRNA to immune cells for <i>in vivo</i> cell therapy#676323Europe PMC
• Self-amplifying RNA (saRNA) and circular RNA (circRNA) vaccines: Progress, evidence gaps, and translational pathways for durable and scalable immunization#202205Europe PMC
• Anti-miRNA103/107 encapsulated in transferrin-conjugated lipid nanoparticles crosses blood-brain barrier and reduces brain ischemic damage#288360IRIS
• Charge-switching ionizable lipids lower the toxicity of lipid nanoparticles#922243eScholarship
• CS-121 APOC3 Base Editing in FCS#868094ClinicalTrials.gov
• Table 1_Functional-genomic prioritization identifies MED12 as a candidate RNAi vulnerability in acute myeloid leukemia: evaluation of a T22 peptide-functionalized LNP-siRNA formulation.xlsx#1052877Figshare
• Table 3_Functional-genomic prioritization identifies MED12 as a candidate RNAi vulnerability in acute myeloid leukemia: evaluation of a T22 peptide-functionalized LNP-siRNA formulation.xlsx#1052878Figshare
• Table 2_Functional-genomic prioritization identifies MED12 as a candidate RNAi vulnerability in acute myeloid leukemia: evaluation of a T22 peptide-functionalized LNP-siRNA formulation.xlsx#1052879Figshare
• Supplementary file 1_Functional-genomic prioritization identifies MED12 as a candidate RNAi vulnerability in acute myeloid leukemia: evaluation of a T22 peptide-functionalized LNP-siRNA formulation.docx#1052876Figshare
• A Clinical Trial in Adult Participants Without HIV and in Overall Good Health to Evaluate the Safety and Immunogenicity of CD4BS CH505M5 Pr-NP1 Followed by CH505 TF chTrimer Boost Both Adjuvanted With Either Lipid Nanoparticles (LNPs) or 3M-052-AF + Alum#363665ClinicalTrials.gov
• Figure 1 from: Abuhaliema A, Gharaibeh L, Jaradat E, Hammad M, Alshaer W (2026) Non-coding RNAs in gene therapy: mechanisms, delivery strategies, and clinical translation. Pharmacia 73: 1-25. https://doi.org/10.3897/pharmacia.73.e173259#210307Zenodo (CERN)